SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Breast Inflammatory Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Genetic: Transferrin Receptor-Targeted Liposomal p53 cDNA Sponsors:   Northwestern University;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials